PMID- 27127346
OWN - NLM
STAT- MEDLINE
DCOM- 20170117
LR  - 20181113
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Print)
IS  - 0962-9351 (Linking)
VI  - 2016
DP  - 2016
TI  - Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 
      and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable 
      Chronic Obstructive Pulmonary Disease.
PG  - 4173962
LID - 10.1155/2016/4173962 [doi]
LID - 4173962
AB  - OBJECTIVE: To study the effects of low-dose and long-term treatment with 
      erythromycin on IL-17 and IL-23, in peripheral blood and induced sputum, in 
      patients with stable chronic obstructive pulmonary disease (COPD). METHODS: 
      Patients were randomly divided into placebo-treated group, group A (12 months of 
      additive treatment with erythromycin, N = 18), and group B (6 months of additive 
      treatment with erythromycin followed by 6 months of follow-up, N = 18). 
      Inflammatory cells in induced sputum, pulmonary function, and the 6-minute walk 
      distance (6MWD) were analyzed. Concentrations of IL-17 and IL-23 in peripheral 
      blood and sputum were measured using enzyme-linked immunosorbent assays. RESULTS: 
      After treatment, sputum and peripheral blood concentrations of IL-17 and IL-23 
      significantly decreased in groups A and B compared with placebo-treated group. 
      There were no significant differences after erythromycin withdrawal at months 9 
      and 12 in group B compared with placebo-treated group. An increase in 6MWD was 
      observed after treatment. CONCLUSIONS: Erythromycin was beneficial and reduced 
      airway inflammation in COPD patients. Underlying mechanisms may involve 
      inhibition of IL-17 and IL-23 mediated airway inflammation. COPD patients treated 
      with erythromycin for 6 months experienced improved exercise capacity. Finally, 
      treatment for 12 months may be more effective than treatment for 6 months.
FAU - Tan, Caimei
AU  - Tan C
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530021, China.
FAU - Huang, Huijuan
AU  - Huang H
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530021, China.
FAU - Zhang, Jianquan
AU  - Zhang J
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530021, China.
FAU - He, Zhiyi
AU  - He Z
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530021, China.
FAU - Zhong, Xiaoning
AU  - Zhong X
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530021, China.
FAU - Bai, Jing
AU  - Bai J
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530021, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160403
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-23)
RN  - 63937KV33D (Erythromycin)
SB  - IM
MH  - Aged
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Erythromycin/*therapeutic use
MH  - Humans
MH  - Interleukin-17/*blood/metabolism
MH  - Interleukin-23/*blood/metabolism
MH  - Middle Aged
MH  - Pulmonary Disease, Chronic Obstructive/*blood/*drug therapy/metabolism
MH  - Sputum/*chemistry
MH  - Walking/*physiology
PMC - PMC4834156
EDAT- 2016/04/30 06:00
MHDA- 2017/01/18 06:00
PMCR- 2016/04/03
CRDT- 2016/04/30 06:00
PHST- 2016/01/16 00:00 [received]
PHST- 2016/03/10 00:00 [accepted]
PHST- 2016/04/30 06:00 [entrez]
PHST- 2016/04/30 06:00 [pubmed]
PHST- 2017/01/18 06:00 [medline]
PHST- 2016/04/03 00:00 [pmc-release]
AID - 10.1155/2016/4173962 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2016;2016:4173962. doi: 10.1155/2016/4173962. Epub 2016 Apr 3.